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Abstract
Background:  A n  o r a l  c o m b i n e d  f l u o r o p y rimidine anticancer drug, tegafur/gimeracil/oteracil
potassium (S-1), has recently been used alone or in combination for colon cancer.
Case presentation: The patient was a 42-year-old man with sigmoid colon cancer with direct
invasion of the urinary bladder and multiple costal metastases. A diagnosis of T4, M1, stage IV
sigmoid colon cancer was made, and curative resection was considered impossible. S-1 at 50 mg/
m2 was administered by oral route from day 1 to day 14. Irinotecan (CPT-11) at 40 mg/m2 was
administered by intravenous day 1 and 15. This treatment was followed by 2 weeks absent period,
and repeated every 4 weeks. Six cycles of administration were performed in total. Following this
treatment, the multiple costal metastases resolved. Down-staging to T3, M0, stage IIA was
achieved, and curative resection was judged to be possible.
Conclusion: Occasional cases in which S-1/CPT-11 therapy was effective have been recently
reported. The patient's tumor became resectable despite the discovery of colon cancer associated
with bone metastasis at the initial examination, offering hope for cancer patients.
Introduction
The standard chemotherapy for non-resectable advanced
colon cancer is combination chemotherapy with 5-fluor-
ouracil/leucovorin (5-FU/LV) and irinotecan (CPT-11) or
with 5-FU/LV and oxaliplatin (L-OHP) [1-4]. An oral
combined fluoropyrimidine anticancer drug, tegafur/
gimeracil/oteracil potassium (S-1), has recently been used
alone or in combination for colon cancer [5-7]. We
encountered a patient with sigmoid colon cancer with
multiple costal metastases, in whom S-1/CPT-11 combi-
nation therapy was effective and curative resection
became applicable.
Case presentation
The patient was a 42-year-old man with dysuria and
fecaluria from late January 2004, who attended the Urol-
ogy Department of our hospital. Cystoscopy and pelvic
CT suggested a tumor of digestive tract origin invading the
urinary bladder. The patient was referred to the Depart-
ment of Digestive Surgery.
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At the initial examination, height, was 160 cm; body
weight, 63.5 kg; and body surface area, 1.89/m2. Perform-
ance status was grade 0. A fist-size tumor was palpable in
the lower abdominal region. There was no particular past
medical history or familial medical history.
At the initial examination, white blood cell count, was
7,600/µl; red blood cell count, 509 × 103/µl; hemoglobin,
16.4 g/dl; AST, 19 IU/l; ALT, 11 IU/l; creatinin clearance,
185.9 ml/min, C reactive protein, 2.19 mg/dl; CEA, 4.3
ng/ml; and CAl9-9, 7.3 U/ml. Bacterial culture of urine
detected  Escherichia coli and  Klebsiella pneumoniae. No
malignant cells were identified on urine cytoanalysis. Pel-
vic computerized tomography (CT) revealed a mass lesion
measuring 8 cm was present in the pelvis, with direct inva-
sion of the posterior wall of the urinary bladder. Abdom-
inal CT detected no space-occupying lesion in the liver or
swelling of peritoneal lymph nodes.
Colonoscopy revealed a 1/2-circumferential ulcerated
tumor in the sigmoid colon, and a protuberant tumor was
noted on the anal side of the main tumor. Histopatholog-
ically, both tumors were well-differentiated adenocarci-
noma.
99mTc-HMDP bone scintigraphy revealed many lesions
with accumulation in the left ribs, which were diagnosed
as multiple costal metastases (Figure 1A). Chest imaging
showed no abnormal findings.
Based on the above findings, the diagnosis of T4, M1,
stage IV sigmoid colon cancer was made (TNM classifica-
tion), and curative resection was considered impossible.
Colostomy was performed on April 5, 2004, and chemo-
therapy with S-1 and CPT-11 was initiated on April 14. S-
1 at 50 mg/m2 was administered orally from day 1 to day
14. CPT-11 at 40 mg/m2 was administered intravenously
day 1 and 15. This treatment was followed by a 2 week
rest, and was repeated every 4 weeks [7]. Since drug-
induced liver dysfunction (grade 3) and diarrhea (grade
2) developed after completion of the 2nd cycle, the S-1
dose was reduced to 40 mg/m2 after their improvement,
and 6 cycles of administration were performed in total
(total dose: S-1: 7,560 mg as tegafur, CPT-11: 480 mg).
This therapy resulted in resolution of the multiple costal
metastases (Figure 1B), and a 50% reduction of the local
lesion on CT. Down-staging to T3, M0, stage IIA was
achieved, and curative resection was judged to be possi-
ble. A Sigmoidectomy, lymphadenectomy, and partial
cystectomy were performed on January 22, 2005.
On histopathological examination the ulcerated tumor
with a clear margin was a well-differentiated adenocarci-
noma measuring 3 × 3 cm. Subserous retention of mucus
was noted, but the tumor was typed as pT2, ly0, v0, pN0,
indicating the possibility of curative resection. Half of the
tumor was degenerative, necrotic, and fibrotic (Figure 2A
and 2B). The additional cancer on the anal side was a 1.5
cm semipedunculated well-differentiated adenocarci-
noma Tis. The postoperative course was uneventful, and
the patient was discharged on February 4, 2005.
Discussion
Colon cancer is often associated with metastasis to other
organs such as the liver, lung, or brain. Bone metastasis,
on the other hand, is relatively unusual, with a reported
incidence of 4–6% [8,9] and colon cancer with bone
metastasis alone without metastasis to other organs is
rare.
Therapy for non-resectable advanced recurrent colon can-
cer has rapidly progressed since the report by Saltz et al
[1]. The median survival time (MST) obtained with the
previous 5-FU/LV therapy was about 12 months, but pro-
longation of MST to about 20 months by the use of 5-FU/
LV, CPT-11, and oxaliplatin (L-OHP) as key drugs has
been reported [2,3,10,11]. It has also been reported that
the use of 5-FU/LV, CPT-11, and L-OHP together for pri-
mary or secondary therapy and thereafter has prolonged
the survival time [4].
A) 99mTc-HMDP bone scintigraphy showing many lesions  with accumulation in the left ribs, which were diagnosed as  multiple costal metastases Figure 1
A) 99mTc-HMDP bone scintigraphy showing many lesions 
with accumulation in the left ribs, which were diagnosed as 
multiple costal metastases. B) After chemotherapy with S-1 
and CPT-11, the costal metastases have resolved.World Journal of Surgical Oncology 2006, 4:3 http://www.wjso.com/content/4/1/3
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S-1 is an oral anticancer drug, which was developed based
on the biochemical modulation of tegafur by gimeracil
and oteracil. Gimeracil strongly inhibits dihydropyrimi-
dine dehydrogenase, and inhibits 5-FU degradation
approximately 180 times more effectively than uracil in
vitro. Coadministration of gimeracil and tegafur markedly
increases the antitumor activity of tegafur. Oteracil inhib-
its the phosphorylation of 5-FU to 5-fluorouridine-5'-
monophosphate. As oteracil is distributed in the gastroin-
testinal tract after oral administration, it possibly
decreases 5-FU-induced gastrointestinal tract toxicity.
Currently, S-1 is used for cancer of the colon [5,6], stom-
ach and lung [12][13][14,15].
Occasional cases in which S-1/CPT-11 therapy was effec-
tive have been recently reported, and a high response rate
in advanced colorectal cancer has also been reported1. In
our patient, surgery was selected after resolution of multi-
ple bone metastases and improvement of urinary bladder
invasion 7 months after the initiation of therapy. This is a
rare case in which curative resection was performed
despite the discovery of bone metastasis at the initial
examination.
Tegafur/uracil and oral leucovorin therapy achieved sur-
vival comparable to that with 5-FU/LV therapy [16], and
the usefulness of combination therapy with oral fluoropy-
rimidines such as Tegafiri and Tegafox has been demon-
strated [17]. Treatment with monoclonal antibodies such
as bevacizumab has come to be used as primary therapy
[18]. The choices of chemotherapy for colon cancer may
further widen in the future.
The patient's tumor became resectable despite the discov-
ery of colon cancer accompanied by bone metastasis at the
initial examination, offering hope for cancer patients. No
recurrence or metastasis had occurred as of 8 months after
surgery, and the patient has been receiving outpatient
treatment with same regimen and is fully active.
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A) Microscopic image of tumor obtained by colonic biopsy before chemotherapy, showing well-differentiated adenocarcinoma Figure 2
A) Microscopic image of tumor obtained by colonic biopsy before chemotherapy, showing well-differentiated adenocarcinoma. 
B) Microscopic image of surgical specimen after chemotherapy. Half of the tumor shows degeneration, necrosis, and fibrosis.Publish with BioMed Central    and   every 
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